Free Newsletter
Register for our Free Newsletters
Analysis, Inspection and Laboratory
Assisted/Independent Living
Clinical and Nursing Equipment
Design and Manufacture of Medical Equipment
Diagnostics Equipment, Monitoring and Test
Education, Training and Professional Services
Health Education and Patient Management
Health Estates Management
Healthcare Support and Information Services
Hygiene and Infection Control
IT and Communications in Healthcare
Medical Device Technology
Research and Development
Safety and Security
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone

Aporo signs global licensing agreement with mnemoscience for biodegradable shape memory polymers

Aporo Biomedical : 31 January, 2008  (New Product)
Aporo Biomedical has signed an exclusive global licensing agreement with mnemoscience of Aachen, Germany for the German company’s proprietary biodegradable shape memory polymers (BIO-SMP).
Aporo’s goal is to provide significant clinical value by delivering novel transcatheter devices that close defects and then biodegrade over time, leaving behind no permanent implant. Initially, Aporo will use these materials to treat Patent Foramen Ovale (PFO), a type of structural heart disease that involves closing an open tunnel between the upper left and right chambers of the heart.

In the future, the company will use the polymers in devices to treat Atrial Septal Defect (ASD), another structural heart disease, and for vascular closure after catheter-based interventional procedures.

While a PFO typically closes within the first few days after birth, approximately 25 percent of the population has a passageway or hole that remains open. In fact, PFOs may cause an estimated 200,000 strokes per year. PFOs are also believed to be a factor in migraine headaches, which affect 12 percent of the population.

Studies indicate that PFO closure may bring migraine relief. Currently, several transcatheter closure devices are in clinical trials to evaluate PFO closure and the impact on stroke and migraine.

Although minimally invasive catheter-based procedures are relatively short and can provide significant benefits to the patient, there is a growing desire among clinicians to avoid the potential complications and disadvantages from permanently implanting a large device in an otherwise healthy heart. Aporo Biomedical aims to address this concern by delivering a biodegradable device that closes the PFO without leaving a permanent implant.

“The next significant advance in medical technology will be biodegradable devices that disappear once they’ve done their job,” commented Carolyn Patrick, president and CEO of Aporo Biomedical. “As patients are treated younger and live longer, it is even more important for physicians to have options that consider not only the patients’ immediate outcomes and quality of life, but their future medical needs as well. Aporo Biomedical is well-positioned to advance the field of PFO closure with a fully biodegradable device. We look forward to working with mnemoscience and utilising the novel BIO-SMP technology to bring these transformative devices to market.”

“We are delighted to partner with such a skilled and innovative medical device manufacturer for our BIO-SMP technology,” said Christian Palme, CEO, mnemoscience. “Securing high-quality, progressive partners like Aporo Biomedical has been a key focus of our strategic development plan and represents an important milestone in advancing our BIO-SMP commercialisation programme.”
Bookmark and Share
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
   © 2012
Netgains Logo